CRAFA
PEPTIDE & COMPOUND ANALYSIS

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-1042
Issued: 2026-08-28

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

PRODUCT IDENTIFICATION

PRODUCT Retatrutide	SKU / INTERNAL CODE CRF-2026-1042	PRESENTATION Lyophilised powder, 5 mg vial
BATCH NUMBER CRF-2026-1042	SAMPLE RECEIVED 2026-08-20	PRODUCTION DATE 2026-08-15
ANALYSIS DATE 2026-08-26	EXPIRY / RETEST DATE 2028-08-26	MOLECULAR FORMULA (REFERENCE) C221H342N46O68
MOLECULAR WEIGHT (G/MOL; REFERENCE) 4731.36	CAS (REFERENCE) 2381089-83-2	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT Waters Xevo G3	COLUMN C4 2.1×100mm	COLUMN TEMPERATURE 60°C
MOBILE PHASE A 0.1% TFA H2O	MOBILE PHASE B 0.1% TFA ACN	FLOW RATE 0.3 mL/min
DETECTION WAVELENGTH 214 nm	INJECTION VOLUME 5 µL	SAMPLE CONCENTRATION 0.2 mg/mL
DILUENT —	RETENTION TIME (MAIN PEAK) 14.3 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS · LAL

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.6%	PASS
Identity (LC-MS)	4732.4 ±2%	Obs: 4731.20 [M+H]+	PASS
Quantity found	95.0–105.0%	4.83 mg (96.6%)	PASS
Endotoxin	<1.0 EU/mg	<0.8 EU/mg	PASS
Heavy metals	<10 ppm	<5 ppm	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Acceptable for research. Two minor impurities at <1.5% each — typical for early-clinical-stage compound.

crafa

CRAFA